News

New findings from healthcare consulting and technology company D2 Solutions indicate that medication access delays are influencing whether patients initiate prescribed therapies, with confusion and administrative hurdles emerging as key barriers. Based on a survey of 1,000 U.S. adults...

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a...

Japanese pharmaceutical company Otsuka has moved to deepen its presence in the emerging neuroplastogen space through an agreement to acquire Transcend Therapeutics, bringing with it a promising MDMA-based candidate targeting post-traumatic stress disorder (PTSD) and related psychiatric conditions. The...

Novartis has entered into an agreement to acquire biotech firm Excellergy, a move that will bring a next-generation anti-immunoglobulin e (IgE) programme into its pipeline. Excellergy acquisition is structured at up to $2bn in upfront and milestone payments and...

As a life sciences leader, you are uniquely positioned to bridge the gap between innovation and implementation, but the journey to the patient can appear fragmented within traditional hospital systems. For orthopedics, the private practice model has become a...

Regulatory expectations across the life sciences industries are changing, with more focus on clear and measurable exposure data. Starting from early-stage drug development through to large-scale manufacturing, you are expected to show how chemical, biological and physical agents may...

In today’s healthcare and pharmaceutical environment, patient communication directly influences clinical outcomes, brand perception and long-term product success. As therapies become more complex and patient journeys more fragmented, pharmaceutical companies and healthcare providers must ensure that every interaction delivers...